David A. Siegel Aeglea Bio Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.29 - $0.61 $17,980 - $37,820	-62,000 Reduced 22.73%	210,800 $61,000
Q4 2022 Feb 14, 2023	SELL	$0.35 - $1.54 $47,985 - $211,134	-137,100 Reduced 33.45%	272,800 $122,000
Q3 2022 Nov 14, 2022	BUY	$0.38 - $0.81 $67,716 - $144,342	178,200 Added 76.91%	409,900 $216,000
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $35,200 - $187,264	70,400 Added 43.65%	231,700 $117,000
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $230,197 - $587,187	123,100 Added 322.25%	161,300 $371,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $133,700 - $321,644	38,200 New	38,200 $181,000
Q2 2021 Aug 16, 2021	SELL	$6.32 - $8.38 $213,616 - $283,244	-33,800 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.76 - $8.57 $200,096 - $253,672	-29,600 Reduced 46.69%	33,800 $268,000
Q4 2020 Feb 16, 2021	BUY	$7.02 - $9.83 $43,524 - $60,946	6,200 Added 10.84%	63,400 $499,000
Q3 2020 Nov 16, 2020	BUY	$6.51 - $9.33 $94,395 - $135,285	14,500 Added 33.96%	57,200 $406,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $38,496 - $105,983	9,600 Added 29.0%	42,700 $395,000
Q1 2020 May 15, 2020	BUY	$3.51 - $8.48 $702 - $1,696	200 Added 0.61%	33,100 $154,000
Q4 2019 Feb 14, 2020	BUY	$7.23 - $8.55 $122,910 - $145,350	17,000 Added 106.92%	32,900 $251,000
Q3 2019 Nov 14, 2019	BUY	$6.42 - $9.0 $13,482 - $18,900	2,100 Added 15.22%	15,900 $122,000
Q2 2019 Aug 14, 2019	BUY	$6.1 - $8.78 $84,180 - $121,163	13,800 New	13,800 $95,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.